Is C4 Therapeutics Stock a Good Investment?
C4 Therapeutics Investment Advice | CCCC |
- Examine C4 Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research C4 Therapeutics' leadership team and their track record. Good management can help C4 Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact C4 Therapeutics' business and its evolving consumer preferences.
- Compare C4 Therapeutics' performance and market position to its competitors. Analyze how C4 Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if C4 Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about C4 Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in C4 Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if C4 Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine C4 Therapeutics Stock
Researching C4 Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 92.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. C4 Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.07. The entity recorded a loss per share of 1.71. The firm had not issued any dividends in recent years.
To determine if C4 Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding C4 Therapeutics' research are outlined below:
| C4 Therapeutics generated a negative expected return over the last 90 days | |
| C4 Therapeutics has high historical volatility and very poor performance | |
| C4 Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.76 M. Net Loss for the year was (132.49 M) with loss before overhead, payroll, taxes, and interest of (74.85 M). | |
| C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 92.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: C4 Therapeutics Loses -23.14 percent in 4 Weeks, Heres Why a Trend Reversal May be Around the Corner |
C4 Therapeutics Quarterly Liabilities And Stockholders Equity |
|
C4 Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in C4 Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to C4 Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact C4 Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises C4 Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2022-05-05 | 2022-03-31 | -0.58 | -0.65 | -0.07 | 12 | ||
2021-11-10 | 2021-09-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2021-08-11 | 2021-06-30 | -0.59 | -0.51 | 0.08 | 13 | ||
2024-08-01 | 2024-06-30 | -0.37 | -0.26 | 0.11 | 29 | ||
2022-08-04 | 2022-06-30 | -0.69 | -0.56 | 0.13 | 18 | ||
2023-11-01 | 2023-09-30 | -0.66 | -0.52 | 0.14 | 21 | ||
2021-05-13 | 2021-03-31 | -0.63 | -0.49 | 0.14 | 22 |
Know C4 Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as C4 Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading C4 Therapeutics backward and forwards among themselves. C4 Therapeutics' institutional investor refers to the entity that pools money to purchase C4 Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.3 M | State Street Corp | 2024-12-31 | 1.2 M | Silverarc Capital Management, Llc | 2024-12-31 | 1.2 M | Bain Capital Life Sciences Investors, Llc | 2024-12-31 | 1.1 M | Tang Capital Management Llc | 2024-12-31 | 900 K | Two Sigma Advisers, Llc | 2024-12-31 | 884.3 K | Ubs Group Ag | 2024-12-31 | 757.9 K | Goldman Sachs Group Inc | 2024-12-31 | 573.7 K | Two Sigma Investments Llc | 2024-12-31 | 563.8 K | Soleus Capital Management, L.p. | 2024-12-31 | 7 M | Wasatch Advisors Lp | 2024-12-31 | 6.1 M |
C4 Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 187.06 M.Market Cap |
|
C4 Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.48) | (0.50) | |
| Return On Assets | (0.40) | (0.42) | |
| Return On Equity | (0.62) | (0.59) |
Determining C4 Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if C4 Therapeutics is a good buy. For example, gross profit margin measures C4 Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of C4 Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
Evaluate C4 Therapeutics' management efficiency
C4 Therapeutics has return on total asset (ROA) of (0.2061) % which means that it has lost $0.2061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.46) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 27, 2025, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, C4 Therapeutics' Asset Turnover is projected to slightly decrease based on the last few years of reporting.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.46 | 2.38 | |
| Tangible Book Value Per Share | 4.46 | 2.38 | |
| Enterprise Value Over EBITDA | (1.66) | (1.74) | |
| Price Book Value Ratio | 1.03 | 1.08 | |
| Enterprise Value Multiple | (1.66) | (1.74) | |
| Price Fair Value | 1.03 | 1.08 | |
| Enterprise Value | 258.6 M | 245.7 M |
C4 Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 2.961 |
Basic technical analysis of CCCC Stock
As of the 27th of February, C4 Therapeutics owns the Information Ratio of (0.13), variance of 21.25, and Market Risk Adjusted Performance of (0.30). C4 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the entity's future prices.C4 Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific C4 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on C4 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases C4 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
C4 Therapeutics' Outstanding Corporate Bonds
C4 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. C4 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most CCCC bonds can be classified according to their maturity, which is the date when C4 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CF Industries 515 Corp BondUS12527GAF00 | View | |
| CF Industries 495 Corp BondUS12527GAD51 | View | |
| CF INDS INC Corp BondUS12527GAE35 | View | |
| US12527GAH65 Corp BondUS12527GAH65 | View |
Understand C4 Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing C4 Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.63 | |||
| Coefficient Of Variation | (803.02) | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.25 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 22.96 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 8.02 | |||
| Skewness | 0.6967 | |||
| Kurtosis | 0.3331 |
| Risk Adjusted Performance | (0.08) | |||
| Market Risk Adjusted Performance | (0.30) | |||
| Mean Deviation | 3.63 | |||
| Coefficient Of Variation | (803.02) | |||
| Standard Deviation | 4.61 | |||
| Variance | 21.25 | |||
| Information Ratio | (0.13) | |||
| Jensen Alpha | (0.57) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.31) | |||
| Maximum Drawdown | 22.96 | |||
| Value At Risk | (6.03) | |||
| Potential Upside | 8.02 | |||
| Skewness | 0.6967 | |||
| Kurtosis | 0.3331 |
Consider C4 Therapeutics' intraday indicators
C4 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of C4 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
C4 Therapeutics Corporate Filings
F4 | 18th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of February 2025 Other Reports | ViewVerify | |
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 21st of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
CCCC Stock media impact
Far too much social signal, news, headlines, and media speculation about C4 Therapeutics that are available to investors today. That information is available publicly through CCCC media outlets and privately through word of mouth or via CCCC internal channels. However, regardless of the origin, that massive amount of CCCC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of C4 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of C4 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to C4 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive C4 Therapeutics alpha.
C4 Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
C4 Therapeutics Corporate Management
| Paige Mahaney | Chief Officer | Profile | |
| Kelly Schick | Chief Officer | Profile | |
| Isabel Chiu | Senior Development | Profile | |
| Mr MBA | Chief Officer | Profile | |
| Andrew Hirsch | Pres CEO | Profile | |
| Leonard MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share | Quarterly Revenue Growth 0.387 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between C4 Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.